logo
  

T. Rowe Price Group Q1 Allocated Net Income Flat - Quick Facts

T. Rowe Price Group Inc. (TROW) reported that its net income allocated to common stockholders for the first quarter of 2015 was $301.1 million, unchanged from last year.

Quarterly net income rose to $309.5 million, from $304.3 million last year. Earnings per common share grew to $1.13 from $1.12 in the first quarter of 2014.

Net revenues were $1.03 billion, up from $954.6 million in the prior year.

Analysts polled by Thomson Reuters expected the company to report earnings of $1.14 per share and revenues of $1.03 billion for the quarter. Analysts' estimates typically exclude special items.

Assets under management at March 31, 2015 were $772.7 billion, an increase of $25.9 billion from the end of 2014, including market appreciation and income of $24.0 billion and net cash inflows of $1.9 billion.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates. Dr. Reddy's Laboratories Ltd. is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level. According to the U.S. Food and Drug Administration, the recall was due to powder discoloration in some packets leading to decreased potency.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
RELATED NEWS
Follow RTT